Trial · NCT05323656
Results by group68
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 68
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) | Setanaxib 1600 mg and Pembrolizumab 200 mg | Stable Disease | 10 | Participants | |
| Overall Response Rate (ORR) | Placebo and Pembrolizumab 200 mg | Stable Disease | 5 | Participants | |
| Overall Response Rate (ORR) | Setanaxib 1600 mg and Pembrolizumab 200 mg | Progressive Disease | 7 | Participants | |
| Overall Response Rate (ORR) | Placebo and Pembrolizumab 200 mg | Progressive Disease | 14 | Participants | |
| Overall Response Rate (ORR) | Setanaxib 1600 mg and Pembrolizumab 200 mg | Not Evaluable | 1 | Participants | |
| Overall Response Rate (ORR) | Placebo and Pembrolizumab 200 mg | Not Evaluable | 0 | Participants | |
| Duration of Response (DoR) | Setanaxib 1600 mg and Pembrolizumab 200 mg | Duration of Response 25% Percentile | 170 | 80% Confidence Interval 64 to NA | days |
| Duration of Response (DoR) | Placebo and Pembrolizumab 200 mg | Duration of Response 25% Percentile | 46 | 80% Confidence Interval 43 to 79 | days |
| Duration of Response (DoR) | Setanaxib 1600 mg and Pembrolizumab 200 mg | Duration of Response 50% Percentile | NA | 80% Confidence Interval 170 to NA | days |
| Duration of Response (DoR) | Placebo and Pembrolizumab 200 mg | Duration of Response 50% Percentile | 79 | 80% Confidence Interval 49 to NA | days |
| Duration of Response (DoR) | Setanaxib 1600 mg and Pembrolizumab 200 mg | Duration of Response 75% Percentile | NA | 80% Confidence Interval 170 to NA | days |
| Duration of Response (DoR) | Placebo and Pembrolizumab 200 mg | Duration of Response 75% Percentile | 300 | 80% Confidence Interval 79 to NA | days |
| Disease Control Rate (DCR) | Setanaxib 1600 mg and Pembrolizumab 200 mg | 70.4 | 90% Confidence Interval 54.5 to 82.5 | percentage of participants | |
| Disease Control Rate (DCR) | Placebo and Pembrolizumab 200 mg | 50 | 90% Confidence Interval 35.2 to 64.8 | percentage of participants | |
| Overall Survival (OS) | Setanaxib 1600 mg and Pembrolizumab 200 mg | 3 Months | 96 | 80% Confidence Interval 91.3 to 100 | percentage of participants |
| Overall Survival (OS) | Placebo and Pembrolizumab 200 mg | 3 Months | 79 | 80% Confidence Interval 68.6 to 88.5 | percentage of participants |
| Overall Survival (OS) | Setanaxib 1600 mg and Pembrolizumab 200 mg | 6 Months | 92 | 80% Confidence Interval 85.6 to 99.0 | percentage of participants |
| Overall Survival (OS) | Placebo and Pembrolizumab 200 mg | 6 Months | 68 | 80% Confidence Interval 56.5 to 79.2 | percentage of participants |
| Overall Survival (OS) | Setanaxib 1600 mg and Pembrolizumab 200 mg | 9 Months | 88 | 80% Confidence Interval 79.1 to 96.3 | percentage of participants |
| Overall Survival (OS) | Placebo and Pembrolizumab 200 mg | 9 Months | 58 | 80% Confidence Interval 45.9 to 71.0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05323656/results?page=2